312 related articles for article (PubMed ID: 17577299)
1. Diagnosis and management of erectile dysfunction in the primary care setting.
Rosenberg MT
Int J Clin Pract; 2007 Jul; 61(7):1198-208. PubMed ID: 17577299
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
3. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
[TBL] [Abstract][Full Text] [Related]
4. Erectile dysfunction for primary care providers.
Brien JC; Trussell JC
Can J Urol; 2008 Aug; 15 Suppl 1():63-70; discussion 70. PubMed ID: 18700067
[TBL] [Abstract][Full Text] [Related]
5. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction - when tablets don't work.
Smith IA; McLeod N; Rashid P
Aust Fam Physician; 2010 May; 39(5):301-5. PubMed ID: 20485717
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
Fabbri A; Aversa A
Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
[TBL] [Abstract][Full Text] [Related]
9. Erectile dysfunction. A guide to diagnosis and management.
Arduca P
Aust Fam Physician; 2003 Jun; 32(6):414-20. PubMed ID: 12833766
[TBL] [Abstract][Full Text] [Related]
10. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
[TBL] [Abstract][Full Text] [Related]
11. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
Gazzaruso C; Solerte SB; Pujia A; Coppola A; Vezzoli M; Salvucci F; Valenti C; Giustina A; Garzaniti A
J Am Coll Cardiol; 2008 May; 51(21):2040-4. PubMed ID: 18498958
[TBL] [Abstract][Full Text] [Related]
12. Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor?
Savas M; Yeni E; Ciftci H; Topal U; Utangac M; Verit A
J Androl; 2009; 30(5):515-9. PubMed ID: 19234311
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of testosterone in the treatment of erectile dysfunction.
Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
[TBL] [Abstract][Full Text] [Related]
14. Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction.
Brotons FB; Campos JC; Gonzalez-Correales R; Martín-Morales A; Moncada I; Pomerol JM
Int J Impot Res; 2004 Oct; 16 Suppl 2():S26-39. PubMed ID: 15496854
[TBL] [Abstract][Full Text] [Related]
15. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction.
Singh JC; Devasia A; Gnanaraj L; Chacko KN
Natl Med J India; 2005; 18(3):139-43. PubMed ID: 16130616
[TBL] [Abstract][Full Text] [Related]
17. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: results from the 'Cottbus Survey' with 10 000 men.
May M; Gralla O; Knoll N; Fenske S; Spivak I; Rönnebeck C; Hoffmann M; Lenk S; Hoschke B
BJU Int; 2007 Nov; 100(5):1110-5. PubMed ID: 17922788
[TBL] [Abstract][Full Text] [Related]
18. The costs of caring for erectile dysfunction in a managed care setting: evidence from a large national claims database.
Sun P; Seftel A; Swindle R; Ye W; Pohl G
J Urol; 2005 Nov; 174(5):1948-52. PubMed ID: 16217364
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Lobo JR; Nehra A
Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
[TBL] [Abstract][Full Text] [Related]
20. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
